A phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA

Trial Profile

A phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs GSK 2857916 (Primary)
  • Indications Haematological malignancies; Multiple myeloma
  • Focus Adverse reactions; First in man
  • Acronyms DREAMM-1
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Dec 2017 Preliminary results from part 2 of the study (n=35) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Dec 2017 According to a GlaxoSmithKline media release, data from this study were presented at the 59th annual meeting of the American Society for Hematology (ASH).
    • 11 Dec 2017 Results published in the GlaxoSmithKline Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top